期刊名称：HLA
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Online ISSN: 2059-2310
Overview
HLA publishes full-length original articles, brief communications, commentaries and occasional reviews on research in: immunogenetics of cell surface antigens; ontogeny and phylogeny of the immune system; immunogenetics of cell interactions; functional aspects of cell surface molecules and their natural ligands, such as cytokines, adhesion molecules and activation antigens; role of tissue antigens in immune reactions in vitro and in vivo, including experimental and clinical transplantation; and relationships between normal tissue antigens and tumor-associated antigens.The journal emphasizes genetic control of immune response, disease susceptibility and genetics, biochemistry and molecular biology of alloantigens and leukocyte differentiation. Manuscripts are invited on molecules expressed on lymphoid cells, myeloid cells, platelets and non-lineage-restricted antigens. The immunogenetics of histocompatibility antigens in humans and experimental animals and their tissue distribution, regulation and expression in normal and malignant cells and antigens as markers for disease are of major interest.
Aims and Scope
HLA publishes full-length original articles, brief communications, commentaries and reviews covering all aspects of genetic control of immunity. The scope includes functional, biochemical, and genetic studies on molecules of the immune system, including cell surface receptors and their ligands, and encompassing cytokines, and chemokines, adhesion and co-stimulating molecules, antigen receptors such as TcR, NKR, CD1, PAMPs, Igs, KIR, and genes and products of the major histocompatibility complex including classical and non-classical HLA molecules. Papers should describe original research in vitro, or in animal models, or be clinical studies reflecting genetics of immunity in solid organ or haematopoietic stem cell transplantation, autoimmunity, infectious immunity, allergy, tumour immunity, vaccine science, pregnancy and disease susceptibility. The journal emphasis is on understanding genetic control of immunity through:
· Immunogenomics including gene organisation, phylogeny, evolution, regulation, polymorphism particularly where it affects expression and function, population genetics, gene markers (eg.microsatellites and SNPs) and typing applications or methodology.
· Protein or antigen expression and biochemistryof immunologically important molecules including post-translational regulation, cell surface expression, isoforms, serology, tissue expression, cell lineage relationships particularly defined by leucocyte differentiation antigens, cell activation and differentiation markers, myeloid and lymphoid cell surface antigens, platelet antigens, thymic markers and non-lineage cell surface molecules.
· Structure and function of molecules that control immune responsesincluding cell surface molecules and their ligands, adhesion molecules, cytokines, chemokines, antigen receptors such as TcR, immunoglobulins, NKR, Toll-like receptors, HLA, KIR, CD1, MICA/B, PAMPs, Complement and other immune effector molecules. Modulation of immune responses by pathogens such as decoy receptors, cytokine analogs and inhibitors of apoptosis or other cellular functions.
· Immunogenetic tools including new genes, sequences, mAbs, polymorphism databases particularly HLA alleles, population data, HLA-peptide repertoires in health and disease, definition of minor histocompatibility antigens, allelic variants, gene maps and bioinformatics.
Review articles, Commentaries, Brief communications and People in Immunogenetics. Review articles (maximum 12 printed pages) on recent developments in areas covered by the journal are invited. Suggestions are welcomed in the form of a one-page synopsis submitted to the Reviews Editor. Commentaries briefly explore important current topics. Brief communications are encouraged for reporting gene sequences, MHC peptide motifs and studies of monoclonal antibodies and disease susceptibility. People in Immunogenetics (maximum 2 printed pages) highlight the scientific contributions of one or more people in relation to a specific recent event involving the person(s).
Reports of meeting or workshops. Contact the Editor-in-Chief before the meeting to determine acceptability.
Submission of sequence data to GenBank or the European Nucleotide Archive (ENA). Original nucleotide or amino acid sequence data described in manuscripts must also be submitted to GenBank or ENA before submission. Manuscripts containing DNA or protein sequences without an accession number are not accepted. Sequences of new alleles should meet the requirements of international nomenclature committees e.g. New HLA alleles require sequencing of complete genes for their proper definition and should have been named by the WHO Nomenclature Committee for Factors of the HLA System.
Rapid publication.This is a large field, and a journal is needed that can publish the latest results in the shortest possible time. We therefore strive to minimize publication time, ensuring that articles on tissue antigens are gathered quickly in one place and are thereby accessible to everyone interested in this field.
Keywords
HLA, human leukocyte antigen, genetics, immunity, immunogenetics, antigen receptors, infectious immunity, autoimmunity, disease susceptibility, MHC, non-human MHC, transplantation, polymorphism
Abstracting and Indexing Information
- Abstracts in Anthropology (Sage)
- Abstracts on Hygiene & Communicable Diseases (CABI)
- Academic Search (EBSCO Publishing)
- Academic Search Alumni Edition (EBSCO Publishing)
- Academic Search Premier (EBSCO Publishing)
- AgBiotech News & Information (CABI)
- AgBiotechNet (CABI)
- Animal Breeding Abstracts (CABI)
- BIOBASE: Current Awareness in Biological Sciences (Elsevier)
- Biological Abstracts (Clarivate Analytics)
- BIOSIS Previews (Clarivate Analytics)
- CAB Abstracts® (CABI)
- CABDirect (CABI)
- CAS: Chemical Abstracts Service (ACS)
- CSA Biological Sciences Database (ProQuest)
- Current Contents: Life Sciences (Clarivate Analytics)
- Dairy Science Abstracts (CABI)
- Embase (Elsevier)
- Global Health (CABI)
- Helminthological Abstracts (CABI)
- Immunology Abstracts (ProQuest)
- Index Veterinarius (CABI)
- InfoTrac (GALE Cengage)
- Journal Citation Reports/Science Edition (Clarivate Analytics)
- MEDLINE/PubMed (NLM)
- Nutrition Abstracts & Reviews Series A: Human & Experimental (CABI)
- Pig News & Information (CABI)
- Protozoological Abstracts (CABI)
- PubMed Dietary Supplement Subset (NLM)
- Review of Medical & Veterinary Entomology (CABI)
- Review of Medical & Veterinary Mycology (CABI)
- Rural Development Abstracts (CABI)
- Science Citation Index (Clarivate Analytics)
- Science Citation Index Expanded (Clarivate Analytics)
- Tropical Diseases Bulletin (CABI)
- Veterinary Bulletin (CABI)
Instructions to Authors
Author Guidelines
Updated 16 June 2016
HLA
Editor-in-Chief
Steven GE Marsh
Anthony Nolan Research Institute
Royal Free Hospital
London NW3 2QG
United Kingdom
E: steven.marsh@ucl.ac.uk
Please submit your manuscript online: http://mc.manuscriptcentral.com/hla
Submissions are no longer accepted by email
The journal to which you are submitting your manuscript employs a Similarity Detection System comparing your submission against previously published works. By submitting your manuscript to this journal you accept that your manuscript may be screened using this system.
Online Open
OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley InterScience, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://olabout.wiley.com/WileyCDA/Section/id-406241.html.
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://authorservices.wiley.com/bauthor/onlineopen_order.asp.Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
Copyright
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. The corresponding author MUST submit the CTA as it is a requirement for publication.
For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign.
The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp.
For authors choosing OnlineOpen
If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: >http://www.wiley.com/go/funderstatement.
Additionally, authors are themselves responsible for obtaining permission to reproduce copyright material from other sources.
Publication Ethics
HLA iis a member of the Committee on Publication Ethics (COPE).
Conflicts of Interest
When submitting a manuscript, authors are responsible for disclosing all financial and personal relationships that could be viewed as presenting a potential conflict of interest. To prevent ambiguity, all authors must state explicitly whether potential conflicts do or do not exist. This information will be included on the title page of the published article. Authors must include the statement in the manuscript on a conflicts of interest notification page following the title page, providing additional detail, if necessary, in a cover letter accompanying the manuscript.
Authorship
All persons listed as authors must have contributed substantially to the design, performance, analysis, or reporting of the work and are required to indicate their specific contribution. The specific requirements for authorship have been defined by the International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org). Examples of authors’ contributions are: 'designed research/study', 'performed research/study', 'contributed important reagents', 'collected data', 'analyzed data', 'wrote paper' etc.
Acknowledgements
All contributors who do not meet the criteria for authorship must be listed in an acknowledgements section at the end of the manuscript. Financial and material support must also be acknowledged. Authors are required to describe the role of the study sponsor(s), if any, in study design; in collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the manuscript for publication. If the supporting source had no such involvement, the authors should state so. Also, if no specific funding was obtained, this should be stated.
Manuscripts must be written in correct English. Review articles, Letters to the Editor, Commentaries, full-length Original Articles, Brief Communications, New Allele Alerts and articles focusing on People in Immunogenetics are accepted.
Review articles, are generally invited in areas covered by the journal or concerning recent topical developments. Suggestions are welcome in the form of a one page synopsis sent to the Editor-in-Chief at the address shown below.
Steven GE Marsh, Editor-in-Chief HLA
Anthony Nolan Research Institute
Royal Free Hospital
London NW3 2QG
United Kingdom
steven.marsh@ucl.ac.uk
Commentaries briefly explore important current topics.
Brief Communications are encouraged for reporting new gene sequences of functional relevance, MHC peptide motifs and studies of monoclonal antibodies and disease susceptibility.
New Allele Alerts are encouraged for reporting new allele sequences of polymorphic immune response genes.
People in Immunogenetics (maximum 2 printed pages) highlight the scientific contributions of one or more people in relation to a specific event involving the person(s).
Original Articles Full-length papers should consist of: Title page (including full title and short title, all authors and their affiliations, communicating author with full address including e-mail address. All authors must state explicitly whether potential conflicts do or do not exist. This information will be included on the title page of the published article.), Key words, Abstract, Introduction, Material and methods, Results, Discussion, Acknowledgements (including grant and/or other sources of support), References, Tables, Figures and Figure legends. All pages should be numbered consecutively,
beginning with the title page, which should be uploaded with the main body of the paper.
Key words. Four to nine key words for indexing should be given by the author(s) together with the Abstract. They should be placed in alphabetical order and, when possible, adjusted to the medical subject headings of
Index Medicus.
Tables. The tables should be uploaded as a Word file, separate from the text, and titles must be self-explanatory. They should be numbered consecutively with Arabic numerals, and due regard should be paid to the proportions of the printed page.
Figures. Figures should be numbered in sequence with Arabic numerals. A legend (as a Word file) should be supplied for each figure. These should also take into consideration the proportions of the printed page and ensure legibility of any labels if reduction for printing is necessary. Figures should be uploaded as PDF files.
It is the policy of HLA for authors to pay the full cost for the reproduction of their colour artwork. Therefore, please note that if there is colour artwork in your manuscript when it is accepted for publication, Wiley-Blackwell require you to complete and return a Colour Work Agreement form before your paper can be published. This form can be downloaded as a PDF from the Internet. If you are unable to access the Internet, or are unable to download the form, please contact Mrs. Naomi Conneely at: HLA@wiley.com and she will be able to e-mail or fax a form to you. Once completed, please return the form to the address below:
Customer Services (OPI)
John Wiley & Sons Ltd, European Distribution Centre
New Era Estate
Oldlands Way
Bogno Regis, West Sussex
PO22 ONQ
Any article received by Wiley-Blackwell with colour work will not be published until the form has been returned.
References. References follow the American Medical Association (AMA) style i.e, number references consecutively in the order in which they are first mentioned in the text. Identify references in text, tables and legends by Arabic numerals (in parentheses). All authors cited, and only these, must be listed at the end of the paper. List all authors when six or less; when seven or more, list only first three and add 'et al'. The titles of journals should be abbreviated according to the List of journals indexed, printed annually in the January issue of Index Medicus.
Examples:
Journal
Brock JH, Esparza I. Failure of reticulocytes to take up iron from lactoferrin saturated by various methods. Br J Haematol. 1979;42:481-483.
Book
Modlin J, Jenkins P. Decision Analysis in Planning for a Polio Outbreak in the United States. San Francisco, CA: Pediatric Academic Societies; 2004.
Book Chapter
Solensky R. Desensitization and treatment of reactions to antibiotics and aspirin. In: Lockey P, ed. Allergens and Allergen Immunotherapy. 3rd ed. New York, NY: Marcel Dekker; 2004:585-606.
The Endnote for reference management and formatting can be found here: http://endnote.com/downloads/style/jama-journal-american-medical-association-ama-10th-edition.
Unpublished data, not yet in press, should not be included in the list of references. They may be referred to in the text as '(unpublished data)' or '(personal communications)'.
Abbreviations and symbols. Use Chemical Abstracts as a guide for abbreviations and symbols. All units must be metric. The following examples illustrate preferred abbreviations: 37°C, 3H, 14C, min (for minutes), h (for hours), ml, g.
Scientific names and nomenclature. Official or standardized nomenclature should be used whenever available (e.g. the CD nomenclature for leukocyte differentiation antigens; official HLA Nomenclature). Original nucleotide or amino acid sequence data described in manuscripts must be submitted to ENA/GenBank/DDBJ before submission. Manuscripts containing DNA or protein sequences without accession number are not accepted. Sequences of new alleles should meet the requirements of international nomenclature committees e.g. New HLA alleles require sequencing of complete genes for their proper definition and should have been named by the WHO Nomenclature Committee for Factors of the HLA System.
Brief Communicationsmust not exceed 10 type-written pages and must not be divided into sections. Brief communications should include a Title page, as described above for Original Articles. Please also include an Abstract (not to exceed 120 words). The first paragraph should state the purpose of the report. Description of methods or technical notes should preferably be in the legends to tables and figures. Brief communications are encouraged for brief reports describing MHC peptide motifs and studies of monoclonal antibodies and disease susceptibility. They may contain important negative issues or might serve to reasonably discourage wasted effort by other researchers.
New Allele Alerts. All reports confined to describing new alleles will be published under the heading New Allele Alert and are not formally peer reviewed. New allele alerts are designed to provide rapid publication of new HLA and other gene alleles. New allele reports should have no more than five authors.
Title: 100 characters maximum. Title must be concise and descriptive (not declarative). Do not include a link to the footnote in the title.
Summary statement: of no more than 15 words must be supplied.
Words: 600 words maximum
References: 6 references maximum
Figure: 1 figure or table maximum
Key words: 5 maximum, listed in alphabetical order
New Allele submissions are not formally peer reviewed but require editorial assessments to ensure proper English syntax, compliance with guidelines for New Allele Alerts, and appropriate allele nomenclature approved by the WHO Nomenclature Committee for Factors of the HLA system or other relevant nomenclature body.
People in Immunogenetics articles should not exceed 2 printed pages.
Letters to the Editor should not exceed 2 printed pages and should contain figures and tables only if completely necessary to the information contained within the letter.
Reports of meetings or workshops
Contact the Editor before the meeting to determine acceptability.
Proofs. The corresponding author will receive an e-mail alert containing a link to a website. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (Portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following web site: http://www.adobe.com/products/acrobat/readstep2.html.
This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof. Hard copy proofs will be posted if no e-mail address is available. Excessive changes made by the author in the proofs, excluding typesetting errors, will be charged separately.
Offprints. Authors can download an electronic PDF offprint of their article upon publication through Wiley-Blackwell’s Author Services. Additional paper offprints may be ordered online at http://offprint.cosprinters.com/blackwell
Early View. HLA is covered by Wiley-Blackwell's Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.
Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive and e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit authorservices.wiley.com/bauthor for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
Note to NIH grantees. Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate.
Author Material Archive Policy. Please note that unless specifically requested, Wiley-Blackwell will dispose of all hardcopy or electronic material submitted two months after publication. If you require the return of any material submitted, please inform the editorial office or production editor as soon as possible if you have not already done so.
Disclaimer. The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher and Editors of the products advertised.
HLA collaborates with Wiley’s open access journal Immunity, Inflammation and Disease, to enable rapid publication of good quality research that we are unable to accept for publication. Authors will be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editor of Immunity, Inflammation and Disease. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. The Editor of Immunity, Inflammation and Disease will accept submissions that report well-conducted research which reaches the standard acceptable for publication. Immunity, Inflammation and Disease is a Wiley Open Access journal and article publication fees apply. For more information please go to www.immunityinflammationdisease.com.
Editorial Board
Editor-in-Chief
Steven GE Marsh
Anthony Nolan Research Institute
Royal Free Hospital
London NW3 2QG
United Kingdom
E: steven.marsh@ucl.ac.uk
Editorial Office
HLA Editorial Office
Naomi Conneely
T: +44 7597 236248
E: HLA@wiley.com
Reviews Editor
Katharina Fleischhauer
Universitätsklinikum Essen
Institute for Experimental Cellular Therapy
Hufelandstraße 55
45122 Essen
Germany
Tel: +49 201 / 723-4582
Fax: +49 201 / 723-4546
E-mail: katharina.fleischhauer@uk-essen.de
Section Editors
Katharina Fleischhauer, Germany - HLA function
John Hammond, UK - Non-human MHC
Sebastiaan Heidt, The Netherlands - HLA in solid organ transplantation
Benedicte Lie, Norway - HLA and Disease
Alicia Sanchez-Mazas, Switzerland - HLA polymorphism in populations
Dianne De Santis, Australia - HLA and diagnostic technology
Luca Vago, Italy - HLA in hematopoietic stem cell transplantation
Carlos Vilches, Spain - KIR polymorphism, structure and function
Editorial Board
R. Blasczyk*, Germany
S. Buus, Denmark
S. Caillat-Zucman, France
M. Carrington, USA
D. Charron, France
F. H. J. Claas*, The Netherlands
L. D’Orsogna, Australia
R. Duquesnoy, USA
S. Ferrone, USA
F. Garrido*, Spain
P. A. Gourraud, France
L. Gragert, USA
J. A. Hansen, USA
C. K. Hurley, USA
J. Kaufman, UK
L. Lanier, USA
A-M. Little*, UK
J. A. López de Castro, Spain
J. McCluskey, Australia
J. A. Madrigal, UK
N. Mehra, India
D. Middleton, UK
C. Muller*, Germany
E. Naumova*, Bulgaria
P. Parham, USA
H-G. Rammensee, Germany
A. Sette, USA
B. Shaw, USA
L. Solid, Norway
B. Tait, Australia
A. Tambur, USA
J-M. Tiercy*, Switzerland
M. G. J. Tilanus*, The Netherlands
K. Tokunaga, Japan
J. Trapani, Australia
J. Trowsdale, UK
*Nominated by EFI.
|
刊名字顺( Alphabetical List of Journals):
返回页首 